Age-related macular degeneration (AMD) treatment has evolved through anti-VEGF therapies for wet AMD, and more recently, complement inhibitors for geographic atrophy in dry AMD. The 2023 approvals of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) for geographic atrophy ended decades without effective treatments for advanced dry AMD. Research continues with longer-acting anti-VEGF therapies and additional approaches for both AMD types. For AMD patients, clinical trials for macular degeneration offer access to investigational therapies. This guide covers how to find AMD trials, active research areas, and resources.
Categories of AMD trials
Active AMD trials in 2026 include:
Long-acting anti-VEGF therapies: Beyond aflibercept and ranibizumab, longer-duration formulations (faricimab, port delivery system, gene therapy).
Geographic atrophy treatments: Beyond pegcetacoplan and avacincaptad, additional complement inhibitors and other mechanisms.
Gene therapy: AAV-based gene therapy for AMD aimed at sustained anti-VEGF expression.
Stem cell approaches: RPE cell replacement therapies in early-stage trials.
Combination therapies: Anti-VEGF combined with other agents.
Drusen and intermediate AMD: Trials targeting earlier disease before vision loss.
Where to find AMD trials
Resources:
- ClinicalTrials.gov
- BrightFocus Foundation
- American Academy of Ophthalmology
- Major academic ophthalmology programs
Typical eligibility
Common inclusion criteria:
- Confirmed AMD with specific type (wet or dry/GA)
- Specific lesion characteristics on imaging
- Visual acuity in specified range
Common exclusion criteria:
- Other significant retinal diseases
- Recent intraocular surgery
- Significant media opacities preventing imaging
- Specific prior therapy (varies)
Frequently Asked Questions
Are wet and dry AMD trials separate?
Generally yes. Different mechanisms drive each, and trials are typically subtype-specific.
Can I be in an AMD trial if I’m receiving anti-VEGF injections?
Some trials test additional therapies on top of standard anti-VEGF; others require switch.
Are gene therapy trials for AMD available?
Yes, in active clinical development at major academic centers.
What about stem cell trials?
Active research area in early-stage trials. Be cautious of unregulated stem cell clinics.
How long do AMD trials typically last?
Phase 3 trials are typically 1-2 years given the chronic nature of AMD progression.
The bottom line on AMD trials
AMD research is active with longer-acting anti-VEGF, geographic atrophy treatments, and emerging gene and cell therapies. Academic ophthalmology programs provide trial resources.